Literature DB >> 21635674

GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice.

C G Jolivalt1, M Fineman, C F Deacon, R D Carr, N A Calcutt.   

Abstract

AIM: Glucagon-like peptide-1 (GLP-1) is an incretin hormone that induces glucose-dependent insulin secretion and may have neurotrophic properties. Our aim was to identify the presence and activity of GLP-1 receptors (GLP-1Rs) in peripheral nerve and to assess the impact of GLP-1R agonists on diabetes-induced nerve disorders.
METHODS: Tissues were collected from streptozotocin-diabetic rats. GLP-1R function was assessed by incubating tissues from normal and diabetic rats with GLP-1R agonists and antagonists and measuring induction of ERK1/2 phosphorylation by Western blot. Streptozotocin-diabetic mice were also treated with the GLP-1R agonist exenatide for 8 weeks to assess the impact of GLP-1R signalling on peripheral nerve function and structure.
RESULTS: GLP-1R protein was detected in rat dorsal root ganglia and the neurons and Schwann cells of the sciatic nerve. Protein levels were not affected by streptozotocin-induced diabetes. GLP-1R agonists did not signal via ERK1/2 in sciatic nerve of normal rats. However, GLP-1R agonists significantly increased pERK1/2 levels in sciatic nerves from diabetic rats, indicating that GLP-1Rs are functional in this tissue. Exenatide treatment did not affect blood sugar, insulin levels or paw thermal response latencies in either control or diabetic mice. However, the reductions of motor nerve conduction velocity and paw intraepidermal fibre density seen in diabetic mice were attenuated by exenatide treatment.
CONCLUSIONS: These data show that the peripheral nerve of diabetic rodents exhibits functional GLP-1R and suggest that GLP-1R-mediated ERK-signalling in sciatic nerve of diabetic rodents may protect large motor fibre function and small C fibre structure by a mechanism independent of glycaemic control.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21635674      PMCID: PMC3177968          DOI: 10.1111/j.1463-1326.2011.01431.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  47 in total

1.  Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Authors:  W O Creutzfeldt; N Kleine; B Willms; C Orskov; J J Holst; M A Nauck
Journal:  Diabetes Care       Date:  1996-06       Impact factor: 19.112

2.  Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

Authors:  Hisko Oeseburg; Rudolf A de Boer; Hendrik Buikema; Pim van der Harst; Wiek H van Gilst; Herman H W Silljé
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

3.  A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy.

Authors:  T Purves; A Middlemas; S Agthong; E B Jude; A J Boulton; P Fernyhough; D R Tomlinson
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

Review 4.  Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.

Authors:  Christian Holscher
Journal:  Recent Pat CNS Drug Discov       Date:  2010-06

5.  Signalling pathways involved in the stimulation of glycogen synthesis by insulin in rat hepatocytes.

Authors:  M Peak; J J Rochford; A C Borthwick; S J Yeaman; L Agius
Journal:  Diabetologia       Date:  1998-01       Impact factor: 10.122

6.  Glucose-dependent stimulatory effect of glucagon-like peptide 1(7-36) amide on the electrical activity of pancreatic beta-cells recorded in vivo.

Authors:  J Fernandez; M Valdeolmillos
Journal:  Diabetes       Date:  1999-04       Impact factor: 9.461

7.  Therapeutic efficacy of sonic hedgehog protein in experimental diabetic neuropathy.

Authors:  Nigel A Calcutt; Karen L Allendoerfer; Andrew P Mizisin; Alicia Middlemas; Jason D Freshwater; Monica Burgers; Rigel Ranciato; Jean-Dominique Delcroix; Frederick R Taylor; Renee Shapiro; Kathy Strauch; Henryk Dudek; Thomas M Engber; Alphonse Galdes; Lee L Rubin; David R Tomlinson
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

8.  Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.

Authors:  Heung Yong Jin; Wei Jing Liu; Ji Hyun Park; Hong Sun Baek; Tae Sun Park
Journal:  Arch Med Res       Date:  2009-10       Impact factor: 2.235

9.  Expression of the GLP-1 receptor in mouse, rat, and human pancreas.

Authors:  Ditte Tornehave; Peter Kristensen; John Rømer; Lotte Bjerre Knudsen; R Scott Heller
Journal:  J Histochem Cytochem       Date:  2008-06-09       Impact factor: 2.479

10.  GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.

Authors:  Yazhou Li; TracyAnn Perry; Mark S Kindy; Brandon K Harvey; David Tweedie; Harold W Holloway; Kathleen Powers; Hui Shen; Josephine M Egan; Kumar Sambamurti; Arnold Brossi; Debomoy K Lahiri; Mark P Mattson; Barry J Hoffer; Yun Wang; Nigel H Greig
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

View more
  27 in total

Review 1.  Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Authors:  Kevin L Farmer; Chengyuan Li; Rick T Dobrowsky
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

Review 2.  Food for thought: the role of appetitive peptides in age-related cognitive decline.

Authors:  Jim R Fadel; Corinne G Jolivalt; Lawrence P Reagan
Journal:  Ageing Res Rev       Date:  2013-02-13       Impact factor: 10.895

Review 3.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

4.  Exendin-4 protects Aβ(1-42) oligomer-induced PC12 cell apoptosis.

Authors:  Chen Qiu; Yan-Ping Wang; Xiao-Dong Pan; Xiao-Ying Liu; Zhou Chen; Li-Bin Liu
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

5.  Liraglutide Promotes Cortical Neurite Outgrowth via the MEK-ERK Pathway.

Authors:  Meng Li; Shilun Li; Yukun Li
Journal:  Cell Mol Neurobiol       Date:  2015-04-11       Impact factor: 5.046

6.  Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA.

Authors:  Masami Tsukamoto; Naoko Niimi; Kazunori Sango; Shizuka Takaku; Yasushi Kanazawa; Kazunori Utsunomiya
Journal:  Histochem Cell Biol       Date:  2015-05-31       Impact factor: 4.304

Review 7.  Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.

Authors:  Isidro Salcedo; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

8.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

9.  Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.

Authors:  Mamta Jaiswal; Catherine L Martin; Morton B Brown; Brian Callaghan; James W Albers; Eva L Feldman; Rodica Pop-Busui
Journal:  J Diabetes Complications       Date:  2015-07-17       Impact factor: 2.852

Review 10.  Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy.

Authors:  Kyung Ae Lee; Tae Sun Park; Heung Yong Jin
Journal:  Endocrine       Date:  2020-09-07       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.